ArticlePharmaceutical research2025
Fabrication and Evaluation of Thermoresponsive GPNMB-Hydrogels as an Innovative Osteogenic Therapeutic Strategy.
Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeEarlier studies have reported the ability of GPNMB protein (GPNMB) to promote osteoblast differentiation and function. However, the realization of clinical potential of GPNMB in bone regeneration will require suitable delivery systems to overcome challenges pertaining to poor dosing and poor retention at target sites. Distribution of osteogenic therapeutics away from the desired bone regeneration sites has been linked to serious adverse effects.
methodWe developed thermoresponsive GPNMB-hydrogels using PLA-b-PEG-b-PLA copolymer (10-30% w/v) and demonstrated the ability to undergo solution-to-gel transition at physiologically relevant temperatures. The hydrogel formulations were characterized by vial inversion techniques, dynamic light scattering, rheological assessments and bioretention studies. GPNMB loading (1-10 µg/mL) did not interfere with hydrogel's thermo-reversibility and viscoelastic behaviors as obtained from rheological strain and frequency sweep tests.
resultsThe in-vitro release of GPNMB reflected a diffusion-controlled kinetic and is supported by hydrogel degradation pattern involving a rapid loss of the PEG units throughout the 8-week period and a delayed degradation of the PLA units. In-vivo long- and short-term safety studies, following GPNMB treatments, showed acceptable serum levels of tissue function and inflammatory markers. There were no detectable signals of ectopic bone formation. Efficacy assessment of GPNMB-hydrogel was based on in-vitro osteoblast differentiation and in-vivo bone regeneration studies in a murine calvaria defect model.
conclusionThe biofunctional properties of GPNMB-hydrogels were supported by enhancement of bone regeneration. Additional studies are warranted to fully examine the potential of GPNMB-hydrogel in bone regeneration using a disease model of fracture healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.